KalVista

KalVista ends a PhII study early after patients suffer severe and life-threatening side effects
Endpoints
Tue, 10/4/22 - 11:37 pm
KalVista
KVD824
clinical trials
hereditary angiodema
Regulatory progress for two biotechs stalls as FDA requests more information
MedCity News
Wed, 04/21/21 - 10:30 am
KalVista
Y-mAbs Therapeutics
FDA
KVD824
HAE
FDA slaps a hold on KalVis­ta's PhII study of an HAE drug, rais­ing a red flag on pre­clin­i­cal re­sults
Endpoints
Tue, 04/20/21 - 11:14 am
KalVista
HAE
FDA
clinical trials
KVD824
Mid-stage angioedema hit sends Kalvista though the roof
EP Vantage
Tue, 02/9/21 - 11:23 am
KalVista
HAE
hereditary angiodema
KVD900
Merck passes on KalVista DME candidate
Seeking Alpha
Tue, 02/11/20 - 10:44 am
Merck
KalVista
diabetic macular edema
KVD001
KalVista's diabetic macular edema data falls short — will Merck walk away?
Endpoints
Mon, 12/9/19 - 09:58 am
KalVista
Merck
diabetic macular edema
KVD001
Upcoming events – key tests approach for Biogen and Kalvista
EP Vantage
Fri, 05/24/19 - 10:42 am
Biogen
BIIB098
Tecfidera
multiple sclerosis
KalVista
HAE
Biocryst
BCX7353
KVD900
Giant Merck buddies up with little KalVista on lead drug, igniting stock with a $760M deal
Endpoints
Tue, 10/10/17 - 09:50 am
Merck
KalVista
KVD001
diabetic macular edema
Upstart biotech banks $13M for new eye drugs
Fierce Biotech
Tue, 08/23/11 - 07:30 pm
eye health
ophthalmology
KalVista
Novo A/S
SV Life Sciences